Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07397949
PHASE4

Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery

Sponsor: Samsung Medical Center

View on ClinicalTrials.gov

Summary

This clinical trial is designed to compare two commonly used eye drop treatments for dry eye disease in patients undergoing cataract surgery. Dry eye disease is common in people who need cataract surgery and may worsen before or after surgery, causing eye discomfort, blurred vision, and unstable vision. Proper management of dry eye before and after surgery may help improve eye comfort and the accuracy of vision outcomes. In this study, patients with mild to moderate dry eye disease who are scheduled for cataract surgery will be randomly assigned to receive one of two treatments: Rebamipide eye drops, or Diquafosol eye drops Participants will begin using the assigned eye drops one month before cataract surgery and continue treatment for three months after surgery. The eye drops will be used only in the eye undergoing surgery. Researchers will examine whether one treatment is as effective as the other in improving tear film stability and reducing dry eye symptoms around the time of cataract surgery. Eye examinations and questionnaires will be performed before surgery, on the day of surgery, and during follow-up visits after surgery. The information gained from this study may help doctors choose the most appropriate treatment for managing dry eye disease in patients undergoing cataract surgery.

Official title: A Randomized Noninferiority Trial Comparing Rebamipide and Diquafosol for Perioperative Dry Eye Management in Cataract Surgery

Key Details

Gender

All

Age Range

40 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-03

Completion Date

2027-03

Last Updated

2026-02-09

Healthy Volunteers

No

Interventions

DRUG

Rebamipide 2% ophthalmic solution

Topical administration to the surgical eye, four times daily.

DRUG

Diquafosol 3% ophthalmic solution

Topical administration to the surgical eye, four times daily.

Locations (1)

Samsung Mec

Seoul, Seoul, South Korea